IL200478A - Kif20a-derived peptide compounds - Google Patents

Kif20a-derived peptide compounds

Info

Publication number
IL200478A
IL200478A IL200478A IL20047809A IL200478A IL 200478 A IL200478 A IL 200478A IL 200478 A IL200478 A IL 200478A IL 20047809 A IL20047809 A IL 20047809A IL 200478 A IL200478 A IL 200478A
Authority
IL
Israel
Prior art keywords
derived peptide
peptide vaccines
kif20a
kif20a derived
vaccines
Prior art date
Application number
IL200478A
Other languages
English (en)
Hebrew (he)
Other versions
IL200478A0 (en
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of IL200478A0 publication Critical patent/IL200478A0/en
Publication of IL200478A publication Critical patent/IL200478A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
IL200478A 2007-02-21 2009-08-18 Kif20a-derived peptide compounds IL200478A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21
PCT/JP2008/000290 WO2008102557A1 (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Publications (2)

Publication Number Publication Date
IL200478A0 IL200478A0 (en) 2010-04-29
IL200478A true IL200478A (en) 2015-11-30

Family

ID=39709837

Family Applications (10)

Application Number Title Priority Date Filing Date
IL200478A IL200478A (en) 2007-02-21 2009-08-18 Kif20a-derived peptide compounds
IL219047A IL219047A0 (en) 2007-02-21 2012-04-04 Peptide vaccines for cancers expressing tumor-associated antigens
IL219045A IL219045A0 (en) 2007-02-21 2012-04-04 Peptide vaccines for cancers expressing tumor-associated antigens
IL219046A IL219046A (en) 2007-02-21 2012-04-04 Kntc2 peptide derivatives
IL219041A IL219041A (en) 2007-02-21 2012-04-04 Vaccination of peptide derivatives ect2
IL219043A IL219043A (en) 2007-02-21 2012-04-04 Epha4-derived peptide compounds
IL219042A IL219042A (en) 2007-02-21 2012-04-04 Epha4-derived peptide compounds
IL219044A IL219044A (en) 2007-02-21 2012-04-04 Hig2-derived peptide compounds
IL219048A IL219048A (en) 2007-02-21 2012-04-04 Peptide compounds derived from urcl10
IL219040A IL219040A (en) 2007-02-21 2012-04-04 Peptide compounds derived from (cadherin3 (cdh3)

Family Applications After (9)

Application Number Title Priority Date Filing Date
IL219047A IL219047A0 (en) 2007-02-21 2012-04-04 Peptide vaccines for cancers expressing tumor-associated antigens
IL219045A IL219045A0 (en) 2007-02-21 2012-04-04 Peptide vaccines for cancers expressing tumor-associated antigens
IL219046A IL219046A (en) 2007-02-21 2012-04-04 Kntc2 peptide derivatives
IL219041A IL219041A (en) 2007-02-21 2012-04-04 Vaccination of peptide derivatives ect2
IL219043A IL219043A (en) 2007-02-21 2012-04-04 Epha4-derived peptide compounds
IL219042A IL219042A (en) 2007-02-21 2012-04-04 Epha4-derived peptide compounds
IL219044A IL219044A (en) 2007-02-21 2012-04-04 Hig2-derived peptide compounds
IL219048A IL219048A (en) 2007-02-21 2012-04-04 Peptide compounds derived from urcl10
IL219040A IL219040A (en) 2007-02-21 2012-04-04 Peptide compounds derived from (cadherin3 (cdh3)

Country Status (27)

Country Link
EP (20) EP2570429A3 (Direct)
JP (6) JP5239103B2 (Direct)
KR (8) KR101540000B1 (Direct)
CN (4) CN101663315B (Direct)
AR (1) AR068302A1 (Direct)
AU (1) AU2008218463B2 (Direct)
BR (1) BRPI0808421B1 (Direct)
CA (3) CA2992074C (Direct)
CO (1) CO6190536A2 (Direct)
CY (2) CY1114590T1 (Direct)
DK (3) DK2476694T3 (Direct)
ES (6) ES2541863T3 (Direct)
HR (3) HRP20131044T1 (Direct)
IL (10) IL200478A (Direct)
MX (4) MX2009009022A (Direct)
MY (2) MY173379A (Direct)
NZ (4) NZ579768A (Direct)
PH (1) PH12014501642A1 (Direct)
PL (3) PL2121731T3 (Direct)
PT (2) PT2121731E (Direct)
RU (1) RU2464275C2 (Direct)
SG (3) SG179402A1 (Direct)
SI (3) SI2465864T1 (Direct)
TW (5) TWI610939B (Direct)
UA (1) UA100372C2 (Direct)
WO (1) WO2008102557A1 (Direct)
ZA (1) ZA200905881B (Direct)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4614952B2 (ja) 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
MX2010002018A (es) * 2007-08-20 2010-05-27 Oncotherapy Science Inc Peptido de cdh3 y agente medicinal que comprende al mismo.
EP2313504B1 (en) 2008-06-30 2015-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
SG195571A1 (en) * 2008-10-22 2013-12-30 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
JP5728716B2 (ja) * 2008-12-24 2015-06-03 オンコセラピー・サイエンス株式会社 Ｃ１ｏｒｆ５９ペプチドおよびそれを含むワクチン
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
TW201627003A (zh) * 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
CN105111281A (zh) * 2010-12-02 2015-12-02 肿瘤疗法科学股份有限公司 Tomm34肽及包含它们的疫苗
IN2014DN05803A (Direct) 2011-12-14 2015-05-15 Univ Texas
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
EP2872530A4 (en) 2012-07-10 2016-04-06 Oncotherapy Science Inc KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
JP6255594B2 (ja) * 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
ES2662808T3 (es) 2012-08-31 2018-04-09 Vasculead Inc. Péptido obtenido de PSF1
MX362912B (es) * 2012-09-11 2019-02-22 Oncotherapy Science Inc Péptidos ube2t y vacunas que incluyen los mismos.
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
HK1223971A1 (zh) * 2013-07-12 2017-08-11 大日本住友制药株式会社 肿瘤抗原肽
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
EP3178837B1 (en) 2014-08-04 2021-01-13 Oncotherapy Science, Inc. Urlc10-derived peptide and vaccine containing same
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
CA3018748A1 (en) * 2016-03-31 2017-10-05 Neon Therapeutics, Inc. Neoantigens and methods of their use
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
RS63259B1 (sr) 2017-01-25 2022-06-30 Ose Immunotherapeutics Postupak za proizvodnju stabilne emulzije za isporuku peptida
CN110709508A (zh) * 2017-03-28 2020-01-17 朱正仑 治疗新生性疾病的方法
CN111433355B (zh) * 2017-08-10 2024-03-29 古德T细胞有限公司 用于癌症治疗的t细胞的活化方法
CA3091099C (en) * 2018-02-15 2021-11-23 National University Corporation Asahikawa Medical University Cancer antigen peptide
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) * 2019-12-31 2021-07-16 上海细胞治疗集团有限公司 一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2189028A1 (en) * 1994-04-15 1995-10-26 Gary M. Fox Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1375515A3 (en) * 1997-10-07 2004-04-21 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use thereof
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU1220001A (en) * 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
US7118853B2 (en) 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
US20040236091A1 (en) * 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
MXPA03011979A (es) * 2001-06-18 2005-04-08 Eos Biotechnology Inc Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2003217966A1 (en) * 2002-03-07 2003-10-08 Licentia, Ltd. Lymphatic and blood endothelial cell genes
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AU2003300680A1 (en) * 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
WO2004058153A2 (en) * 2002-12-20 2004-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4614952B2 (ja) * 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
EP2495324B1 (en) * 2004-04-09 2015-03-04 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
US20090075832A1 (en) * 2005-02-24 2009-03-19 Cemines, Inc Compositions and Methods for Classifying Biological Samples
ES2459466T3 (es) * 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
WO2007018047A1 (ja) * 2005-08-09 2007-02-15 Kurume University Hla-a24分子結合性扁平上皮癌抗原由来ペプチド
PL1923463T3 (pl) * 2005-08-09 2012-02-29 Oncotherapy Science Inc Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen
EP1930433B1 (en) 2005-09-13 2016-03-16 Mie University T-cell receptor and nucleic acid encoding the receptor
US20090263832A1 (en) * 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
US7695928B2 (en) * 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
CN105418751B (zh) * 2006-06-16 2019-03-05 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
US20090081659A1 (en) * 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
MX2010002018A (es) * 2007-08-20 2010-05-27 Oncotherapy Science Inc Peptido de cdh3 y agente medicinal que comprende al mismo.
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
CA2775978A1 (en) * 2009-09-29 2011-04-07 Protagen Ag Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof

Also Published As

Publication number Publication date
EP2573110A2 (en) 2013-03-27
EP2476692A2 (en) 2012-07-18
IL200478A0 (en) 2010-04-29
CO6190536A2 (es) 2010-08-19
EP2570430A2 (en) 2013-03-20
NZ591704A (en) 2012-09-28
IL219043A (en) 2014-12-31
EP2476695A3 (en) 2012-12-12
EP2570428A2 (en) 2013-03-20
EP2465867A3 (en) 2012-10-10
EP2476694A3 (en) 2013-04-24
BRPI0808421B1 (pt) 2021-10-05
CN101663315A (zh) 2010-03-03
KR20150116463A (ko) 2015-10-15
KR101540000B1 (ko) 2015-07-29
CA2992074C (en) 2021-01-05
EP2573110A3 (en) 2013-09-04
KR101644871B1 (ko) 2016-08-02
PH12014501642B1 (en) 2015-12-02
EP2476693A2 (en) 2012-07-18
KR20140130507A (ko) 2014-11-10
PL2476694T3 (pl) 2015-04-30
CA2678755C (en) 2016-04-26
HK1134507A1 (en) 2010-04-30
EP2573109A2 (en) 2013-03-27
KR20130023407A (ko) 2013-03-07
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
IL219047A0 (en) 2012-05-31
SI2465864T1 (sl) 2014-12-31
IL219042A (en) 2016-03-31
SG10201506589WA (en) 2015-09-29
EP2567971A2 (en) 2013-03-13
EP2465866A2 (en) 2012-06-20
TWI494319B (zh) 2015-08-01
EP2583976A3 (en) 2013-10-23
SG10201909675QA (en) 2019-11-28
EP2570429A2 (en) 2013-03-20
TWI596109B (zh) 2017-08-21
HK1172345A1 (en) 2013-04-19
HK1172043A1 (en) 2013-04-12
JP5608953B2 (ja) 2014-10-22
JP2010519176A (ja) 2010-06-03
IL219041A0 (en) 2012-05-31
ES2540893T3 (es) 2015-07-14
EP2465864A2 (en) 2012-06-20
AU2008218463B2 (en) 2013-01-17
PL2465864T3 (pl) 2015-03-31
CN104292299B (zh) 2017-09-29
TW201538522A (zh) 2015-10-16
KR101644877B1 (ko) 2016-08-03
CN103351423A (zh) 2013-10-16
ES2530777T3 (es) 2015-03-05
KR20140121489A (ko) 2014-10-15
IL219048A (en) 2015-07-30
TW201623325A (zh) 2016-07-01
WO2008102557A1 (en) 2008-08-28
TWI610939B (zh) 2018-01-11
AR068302A1 (es) 2009-11-11
IL219046A (en) 2015-02-26
TWI438207B (zh) 2014-05-21
EP2476694B1 (en) 2014-11-19
EP2570430A3 (en) 2013-07-10
EP2476693B1 (en) 2014-12-24
EP2476693A3 (en) 2012-10-03
EP2121731A1 (en) 2009-11-25
ES2435194T3 (es) 2013-12-16
IL219045A0 (en) 2012-05-31
CN104292299A (zh) 2015-01-21
CA2919248A1 (en) 2008-08-28
TW201422637A (zh) 2014-06-16
UA100372C2 (ru) 2012-12-25
PT2121731E (pt) 2013-10-24
JP2010209060A (ja) 2010-09-24
ES2527397T3 (es) 2015-01-23
HRP20131044T1 (hr) 2013-12-06
NZ602122A (en) 2014-03-28
MX337456B (es) 2016-03-03
ZA200905881B (en) 2010-05-26
MX337417B (es) 2016-03-03
EP2465865B1 (en) 2016-11-02
AU2008218463A1 (en) 2008-08-28
ES2532708T3 (es) 2015-03-31
DK2121731T3 (da) 2013-10-21
EP2574623A3 (en) 2013-07-17
EP2465865A3 (en) 2013-07-24
TWI615403B (zh) 2018-02-21
IL219040A0 (en) 2012-05-31
EP2583976A2 (en) 2013-04-24
PL2121731T3 (pl) 2014-01-31
EP2573109A3 (en) 2013-06-19
IL219048A0 (en) 2012-05-31
HK1172042A1 (en) 2013-04-12
SI2476694T1 (sl) 2015-02-27
EP2121731B1 (en) 2013-08-14
SI2121731T1 (sl) 2013-10-30
EP2465864A3 (en) 2012-10-03
EP2465867A2 (en) 2012-06-20
EP2465864B1 (en) 2014-10-08
TW201433574A (zh) 2014-09-01
JP5239104B2 (ja) 2013-07-17
KR20160045939A (ko) 2016-04-27
PT2465864E (pt) 2015-01-14
EP2465865A2 (en) 2012-06-20
DK2465864T3 (en) 2014-11-24
PH12014501642A1 (en) 2015-12-02
BRPI0808421A2 (pt) 2017-08-29
JP2014210804A (ja) 2014-11-13
EP2121731A4 (en) 2010-04-21
CA2992074A1 (en) 2008-08-28
EP2476692A3 (en) 2012-12-19
JP5874158B2 (ja) 2016-03-02
EP2594582A2 (en) 2013-05-22
KR101511140B1 (ko) 2015-04-10
EP2594581A3 (en) 2013-08-14
IL219040A (en) 2014-12-31
EP2465867B1 (en) 2015-04-01
IL219041A (en) 2014-12-31
JP5239103B2 (ja) 2013-07-17
IL219044A0 (en) 2012-05-31
SG179402A1 (en) 2012-04-27
EP2574623A2 (en) 2013-04-03
IL219044A (en) 2014-12-31
CY1115841T1 (el) 2017-01-25
NZ602119A (en) 2014-03-28
NZ579768A (en) 2012-03-30
KR20150018895A (ko) 2015-02-24
IL219043A0 (en) 2012-05-31
RU2009135020A (ru) 2011-03-27
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
MY173379A (en) 2020-01-21
KR20150064236A (ko) 2015-06-10
EP2570429A3 (en) 2013-08-28
MX359680B (es) 2018-09-28
EP2594582A3 (en) 2013-08-14
IL219042A0 (en) 2012-05-31
KR20090121349A (ko) 2009-11-25
DK2476694T3 (en) 2014-12-08
EP2476695A2 (en) 2012-07-18
EP2465866A3 (en) 2012-10-10
EP2476694A2 (en) 2012-07-18
KR101543623B1 (ko) 2015-08-11
JP2013116895A (ja) 2013-06-13
RU2464275C2 (ru) 2012-10-20
EP2567971A3 (en) 2013-06-26
HK1172041A1 (en) 2013-04-12
JP5614761B2 (ja) 2014-10-29
MY155029A (en) 2015-08-28
EP2594581A2 (en) 2013-05-22
HRP20150108T1 (hr) 2015-05-08
KR101511134B1 (ko) 2015-04-28
HK1172346A1 (en) 2013-04-19
EP2476692B1 (en) 2015-04-15
HRP20141233T1 (hr) 2015-02-27
TW200844111A (en) 2008-11-16
ES2541863T3 (es) 2015-07-27
HK1172344A1 (en) 2013-04-19
MX2009009022A (es) 2010-03-03
CN103351423B (zh) 2016-09-28
CY1114590T1 (el) 2016-10-05
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
EP2565203A1 (en) 2013-03-06
JP2013091645A (ja) 2013-05-16
JP2016094459A (ja) 2016-05-26
CN101663315B (zh) 2014-10-15

Similar Documents

Publication Publication Date Title
IL200478A (en) Kif20a-derived peptide compounds
IL203899A (en) Foxm1-derived peptide compounds
IL216712A (en) Polypeptides derived from 1depdc
ZA200904923B (en) Vaccine
IL201782A0 (en) Vaccine
GB0717911D0 (en) Vaccine
GB0711858D0 (en) Vaccine
ZA201004303B (en) Vaccine
GB0723712D0 (en) Peptides
AP2010005166A0 (en) Vaccines
IL199622A0 (en) Foxp3 peptide vaccine
EP2123666A4 (en) PEPTIDE
GB0700135D0 (en) Vaccine
GB0710538D0 (en) Vaccine
ZA201103667B (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
ZA201003851B (en) Vaccine
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0716224D0 (en) Peptides for vaccine
GB0707697D0 (en) Vaccine
GB0725107D0 (en) Vaccine
GB0712658D0 (en) Vaccine
GB0712435D0 (en) Vaccine
GB0708522D0 (en) Vaccine
GB0712420D0 (en) Vaccine
GB0712062D0 (en) Vaccine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed